Skip to main content
The Egyptian Journal of Bronchology
Download PDF
  • Original article
  • Open access
  • Published:

Outcome of short-term systemic steroid therapy in chronic obstructive pulmonary disease patients with acute exacerbation

Egyptian Journal of Bronchology volume 12, pages 310–316 (2018)Cite this article

Abstract

Background

There are insufficient data on the optimum duration of systemic steroid therapy during acute exacerbation of chronic obstructive pulmonary disease (COPD).

Aim

To evaluate the outcome of short-term systemic steroid therapy in patients hospitalized with acute exacerbation of COPD and to identify factors associated with treatment failure.

Patients and methods

Fifty severe and very severe COPD patients with acute exacerbation were consecutively included in this study. Patients were assessed by a clinical symptom score, peak expiratory flow rate (PEFR), arterial blood gases and laboratory investigations [blood count indices, high sensitive C-reactive protein, erythrocyte sedimentation rate (ESR) and fibrinogen level]. Short-term systemic steroids were initiated and the outcome was assessed at day 5 of therapy and the patients were classified into treatment success group or failure group.

Results

Treatment failure was observed in 27 (54%) of patients. Patients with treatment failure had significantly higher cough and chest tightness scores, higher partial pressure of CO2 in arterial blood (PaCO2), lower partial pressure of O2 in arterial blood (PaO2), lower PEFR, higher red distribution width (RDW), and higher ESR compared with the success group. By binary logistic regression, higher PaCO2, lower PaO2, and higher ESR were independent risk factors associated with treatment failure. The optimum cutoff level of PaCO2, PaO2, and PEFR associated with treatment failure was more than or equal to 59.5 mmHg, up to 43.5 mmHg, and up to 225 l/min, respectively. ESR first hour of at least 35 and RDW of at least 15.5% were also associated with treatment failure.

Conclusion

Most severe and very severe COPD during acute exacerbations need prolonged course of systemic steroids (>5 days). Clinical evaluation, gasometric parameters, PEFR, RDW, and ESR could be good predictors of treatment failure on short-term systemic steroid.

References

  1. Global strategy for the diagnosis, management, and prevention of COPD:Revised 2017. Global initiative for chronic obstructive lung disease (GOLD). Available at:http://www.goldcopd.org. [Accessed 2017].

  2. Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. Eur Respir J 2007;29:1224–1238.

    Article  CAS  Google Scholar 

  3. Aaron SD, Angel JB, Lunau M, Wright K, Fex C, Le Saux N, et al. Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:349–355.

    Article  CAS  Google Scholar 

  4. CalikogluM, Sahin G, Unlu A, Ozturk C, Tamer L, Ercan B, et al. Leptin and TNF-alpha levels in patients with chronic obstructive pulmonary disease and their relationship to nutritional parameters. Respiration 2004;71:45–50.

    Article  CAS  Google Scholar 

  5. Saetta M, Baraldo S, Zuin R. Neutrophil chemokines in severe exacerbations of chronic obstructive pulmonary disease:fatal chemo-attraction. Am J Respir Crit Care Med 2003;168:911–913.

    Article  Google Scholar 

  6. Zhu J, Qiu YS, Majumdar S, Gamble E, Matin D, Turato G, et al. Exacerbations of bronchitis:bronchial eosinophilia and gene expression for interleukin-4, interleukin-5, and eosinophil chemoattractants. Am J Respir Crit Care Med 2001;164:109–116.

    Article  CAS  Google Scholar 

  7. Tsoumakidou M, Tzanakis N, Chrysofakis G, Kyriakou D, Siafakas NM. Changes in sputum T-lymphocyte subpopulations at the onset of severe exacerbations of chronic obstructive pulmonary disease. Respir Med 2005;99:572–579.

    Article  Google Scholar 

  8. Jadwiga A, Wedzicha A, Terence A, Paul EA, Donaldson GC, Bhowmik A, et al. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost 2000;84:147–361.

    Article  Google Scholar 

  9. Peng C, Tian C, Zhang Y, Yang X, Feng Y, Fan H. C-reactive protein levels predict bacterial exacerbation in patients with chronic obstructive pulmonary disease. Am J Med Sci 2013;345:190–194.

    Article  Google Scholar 

  10. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GKM, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196–204.

    Article  CAS  Google Scholar 

  11. Leuppi JD, Schuetz P, Bingisser R, Bodmer M, Briel M, Drescher T, et al. Short-term vs. conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease:the REDUCE randomized clinical trial. JAMA 2013;309:2223–2231.

    Article  CAS  Google Scholar 

  12. Global Initiative for Obstructive Lung Disease. Global initiative for obstructive lung disease. 2007. Available at:http://www.goldcopd.com. [Accessed 12 July 2007].

  13. Calverley P, Pauwels R, Lofdah CG, Svensson K, Higenbottam T, Carlsson LG, et al. Relationship betweenrespiratory symptomsandmedical treatment in exacerbations of COPD. Eur Respir J 2005;26:406–413.

    Article  CAS  Google Scholar 

  14. Lieberman D, Ben-Yaakov M, Lazarovich Z, Lazarovich Z, Hoffman S, Ohana B, et al. Infectious etiologies in acute exacerbation of COPD. Diagn Microbiol Infect Dis 2001;40:95–102.

    Article  CAS  Google Scholar 

  15. Chow AW, Hall CB, Klein JO, Kammer RB, Meyer RD, Remington JS. Evaluation of new antiinfective drugs for the treatment of respiratory tract infections. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992;15:S62–S88.

    Article  Google Scholar 

  16. Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, et al. International variation in the prevalence of COPD (the BOLD Study):a population-based prevalence study. Lancet 2007;370:741–750.

    Article  Google Scholar 

  17. Connors AF Jr, Dawson NV, Thomas C, Harrell FE Jr, Desbiens N, Fulkerson WJ, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 1996;154:959–967.

    Article  Google Scholar 

  18. Wouters EF. The burden of COPD in the Netherlands:results from the confronting COPD survey. Respir Med 2003;97:S51–S59.

    Article  Google Scholar 

  19. Alia I, de la Cal MA, Esteban A, Abella A, Ferrer R, Molina FJ, et al. Efficacy of corticosteroid therapy in patients with an acute exacerbation of chronic obstructive pulmonary disease receiving ventilatory support. Arch Intern Med 2011;171:1939–1946.

    Article  CAS  Google Scholar 

  20. Crisafulli E, Torres A, Huerta A, Guerrero M, Gabarrús A, Gimeno A, et al. Predicting in-hospital treatment failure (≤7 days) in patients with COPD exacerbationusingantibioticsandsystemicsteroids.COPD 2016;13:82–92.

  21. Daniels JM, Snijders D, de Graaff CS, Vlaspolder F, Jansen HM, Boersma WG, et al. Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010;181:150–157.

    Article  CAS  Google Scholar 

  22. Smith J, Woodcock A. Cough and its importance in COPD. Int J Chron Obstruct Pulmon Dis 2006;1:305–314.

    PubMed  PubMed Central  Google Scholar 

  23. SminaM, SalamA,Khamiees M,Gada P,Amoateng-Adjepong Y,Manthous C. Cough peak flows and extubation outcomes. Chest 2003;124:1–6.

    Article  Google Scholar 

  24. Emerman CL, Cydulka RK. Use of peak expiratory flow rate in emergency department evaluation of acute exacerbation of chronic. Obstruct Pulmon Dis 1996;27:159–163.

    CAS  Google Scholar 

  25. Orio KE, Veesart J, Westermeyer R. The use of peak flow during acute exacerbations of chronic obstructive pulmonary disease in the emergency department. Ann Emerg Med 2004;44:S36–S37.

    Article  Google Scholar 

  26. Perez-Padilla R, Vollmer WM, Vazquez-Garcia JC, Enright PL, Menezes AM, Buist AS, et al. Can a normal peak expiratory flow exclude severe chronic obstructive pulmonary disease?. Int J Tuberc Lung Dis 2009;13:387–393.

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Aktas G, Sit M, Dikbas O, Tekce BK, Savli H, Tekce H, et al. Could red cell distribution width be a marker in Hashimoto’s thyroiditis?. Exp Clin Endocrinol Diabetes 2014;122:572–574.

    Article  CAS  Google Scholar 

  28. Koçak MZ. Evaluation of red cell distribution width levels during acute exacerbation in patients with chronic obstructive pulmonary disease. Biomed Res 2017;28:3009–3011.

    Google Scholar 

  29. Pepys MB, Hirschfield GM. C-reactive protein:a critical update. J Clin Invest 2003;111:1805–1812.

    Article  CAS  Google Scholar 

  30. Perera WR, Hurst JR, Wilkinson TM, Sapsford RJ, Müllerova H, Donaldson GC, et al. Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J 2007;29:527–534.

    Article  CAS  Google Scholar 

  31. Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjærg-Hansen A, Nordestgaard BG. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:250–255.

    Article  CAS  Google Scholar 

  32. Valipour A, Schreder M, Wolzt M, Saliba S, Kapiotis S, Eickhoff P, et al. Circulating vascular endothelial growth factor and systemic inflammatory markers in patients with stable and exacerbated chronic obstructive pulmonary disease. Clin Sci (Lond) 2008;115:225–232.

    Article  CAS  Google Scholar 

  33. Duvoix A, Dickens J, Haq I, Mannino D, Miller B, Tal-Singer R, et al. Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease. Thorax 2013;68:670–676.

    Article  Google Scholar 

  34. Thomas BK, Yuvarajan S. Plasma fibrinogen in chronic obstructive pulmonary disease – a cross sectional study conducted in a Tertiary Care Hospital in Puducherry, India. Br J Med Med Res 2016;14:1–8.

    Article  Google Scholar 

  35. Saldias PF, Diaz PO, Dreyse DJ, Gaggero BA, Sandoval AC, Lisboa BC. Etiology and biomarkers of systemic inflammation in mild to moderate COPD exacerbations. Rev Med Chil 2011;140:10–18.

    Article  Google Scholar 

  36. Koutsokera A, Kiropoulos TS, Nikoulis DJ, Daniil ZD, Tsolaki V, Tanou K, et al. Clinical, functional and biochemical changes during recovery from COPD exacerbations. Respir Med 2009;103:919–926.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Chest, Faculty of Medicine, Assiut University Hospital, 7111, Asyut, Egypt

    Ashraf Zin El-Abdeen, Lamiaa H. Shaaban, Shereen Farghaly MD & Entsar H. Mohammed

  2. Department of Clinical Pathology and Immunology, Faculty of Medicine, Assiut University Hospital, Asyut, Egypt

    Hanan Galal

Authors
  1. Ashraf Zin El-Abdeen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lamiaa H. Shaaban
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shereen Farghaly MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hanan Galal
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Entsar H. Mohammed
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shereen Farghaly MD.

Additional information

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

El-Abdeen, A.Z., Shaaban, L.H., Farghaly, S. et al. Outcome of short-term systemic steroid therapy in chronic obstructive pulmonary disease patients with acute exacerbation. Egypt J Bronchol 12, 310–316 (2018). https://doi.org/10.4103/ejb.ejb_104_17

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.4103/ejb.ejb_104_17

Key Words